Skip to main content
. 2020 Mar 26;9(4):912. doi: 10.3390/jcm9040912

Figure 1.

Figure 1

Schematic representation of the main routes, tissue biotargets, mode of actions, and effects of glucose-lowering medications, and their impact on cardiovascular risk in patients with Type 2 Diabetes. The data are obtained from both scientific literature and CardioVascular Outcome Trials, carefully assessing the cardiovascular safety of the main newest glucose-lowering medications.